Creating Value Across the Medical Device Lifecycle
4 – 5 November 2026 in Brussels & Online
Join international experts, healthcare professionals and key stakeholders for two days of knowledge sharing, discussion and collaboration around value creation across the medical device lifecycle.
From innovation and development to market access, reimbursement, patient access and real-world outcomes, the ICEPS 2026 Conference will explore how evidence and collaboration can support better decisions and ultimately improve outcomes for patients
ABOUT THE CONFERENCE
The ICEPS 2026 Conference will bring together international experts and stakeholders from across the medical device ecosystem to explore this year’s theme:
Creating Value Across the Medical Device Lifecycle
Creating value goes beyond bringing an innovative medical device to market. It requires the right evidence, perspectives and decisions throughout the entire lifecycle — from innovation and clinical development to regulatory strategy, Health Technology Assessment (HTA), Health Economics and Outcomes Research (HEOR), reimbursement, patient access and real-world outcomes.
Over two days, the conference will provide a collaborative forum to share experience, discuss evolving challenges and explore how evidence can support better decision-making and ultimately deliver meaningful value for patients and healthcare systems.
WHY ATTEND?
- Gain new perspectives
Hear from international experts and stakeholders across the medical device ecosystem. - Connect the dots across the lifecycle
Explore how clinical evidence, regulatory strategy, HTA, HEOR, reimbursement and market access increasingly interact. - Learn from real-world experience
Discover practical insights, case studies and approaches that can be applied beyond the conference. - Exchange & connect
Meet peers, experts and decision-makers, share experiences and build new professional connections. - Shape the conversation
Take part in discussions on how we can collectively create greater value for patients and healthcare systems.
CONFERENCE HIGHLIGTHS
Innovation & Development
HEOR
Clinical Evidence
Market Access & Reimbursement
Regulatory Strategy
Patient Access
Health Technology Assessment (HTA)
Real-World Evidence & Outcomes
Call for speaker
Would you like to contribute to the ICEPS 2026 Conference?
We invite experts, thought leaders and practitioners to share to share their experience, insghts and perspectives on creating value across the metical device lifecycle.
Programme in Development
Additional topics, sessions and speakers will be announced progressively
CONFERENCE AGENDA
Agenda in Development
This agenda will be updated regularly. Stay tuned!
DAY 1 - WEDNESDAY, 4 NOVEMBER 2026
08.30
09.00
Registration
xxx
xxx
Welcome & Keynote
Danielle Giroud – MD-Clinicals, WMDO & ICEPS Chairwoman
Welcome note ICEPS
xxx
xxx
TBD
TBD
Keynote Medical Devices
xxx
xxx
TBD
TBD
Keynote In Vitro Diagnostics
xxx
xxx
TBD
TBD
TBD
10.30
11.00
COFFEE BREAK
xxx
xxx
Evolution of Clinical Evidence in the International
TBD
Is Europe now getting settled?
xxx
xxx
TBD
TBD
No all Medical Devices require identical clinical evidence
xxx
xxx
TBD
TBD
Clinical Evidence for IVD – too much or not enough?
xxx
xxx
TBD
TBD
Panel discussion
12.30
13.30
LUNCH BREAK
xxx
xxx
Clinical Evidence Refined
Mark Gumbridge – Medicines and Healthcare products Regulatory Agency
Sufficient clinical evidence when considering sub-populations, what do regulators expect
xxx
xxx
TBD
TBD
A statistical analysis plan, FAS and PP are these sufficient approaches?
xxx
xxx
TBD
TBD
RWD contribution to refining clinical evidence
xxx
xxx
TBD
TBD
RWD guidance to help?
xxx
xxx
TBD
TBD
Panel discussion
15.30
16.00
COFFEE BREAK
xxx
xxx
TBD
Carlos Galamba – MDx & ICEPS Board Member
From sample to result: Global IVD study monitoring under ISO 20916
xxx
xxx
Presentation Title
Speaker Name – Organisation
GenAi Prompt engineering: best practices for clinical evidence professionals
xxx
xxx
TBD
TBD
TBD
17.30
20.00
Closing + Network Apéritif
Agenda in Development
This agenda will be updated regularly. Stay tuned!
DAY 2 - THURSDAY, 5 NOVEMBER 2026
xxx
xxx
Clinical Evidence - Patient Perspective
TBD
Are patients sufficiently informed?
xxx
xxx
TBD
TBD
Do we listen to patients when developing medical devices
xxx
xxx
TBD
TBD
Clinical investigations – patient information – userfriendly?
xxx
xxx
TBD
TBD
TBD
10.30
11.00
COFFEE BREAK
xxx
xxx
In Silico - A Buzz or True Contribution to Clinical Evidence
Martha De Cunha Maluf Burgman
In-Silico Clinical Trials implementation and adoption of in silivo evidence in regulatory pathways
xxx
xxx
TBD
TBD
TBD
xxx
xxx
TBD
TBD
TBD
xxx
xxx
TBD
TBD
Panel discussion
12.30
13.30
LUNCH BREAK
xxx
xxx
Regulatory Approval: What's next?
Michael LoPresti – GinePro & ICEPS Board Member
Post-Launch evidence and reimbursement revisions for medical devices in Japan – Insights from 2026 revisions
xxx
xxx
TBD
TBD
Pre-market steps for reimbursement in the EU
xxx
xxx
TBD
TBD
Panel Discussion
xxx
xxx
TBD
TBD
Panel discussion
15.30
16.00
COFFEE BREAK
xxx
xxx
Bridging the gap between regulations and science
TBD
Developing clinical investigations designs that fit both
xxx
xxx
TBD
TBD
How does compliance during clinical investigations contribute to clinical evidence
xxx
xxx
TBD
TBD
Physician inventors – combining medicine with innovation
16.30
17.30
Closing
Agenda in Development
This agenda will be updated regularly. Stay tuned!
SPEAKERS
Meet the experts and thought leaders joining us at the ICEPS 2026 Conference
Danielle Giroud
MD-Clinicals, WMDO &ICEPS Chairwoman
Carlos Galamba
MDx & ICEPS Board Member
Michael LoPresti
GinePro & ICEPS Board MemberSPONSORS & PARTNERS
Join us as a sponsor or partner and connect with an international community of experts and stakeholders across the medical device ecosystem.
PRACTICAL INFORMATION
DATES
4-5 November 2026
VENUE
Silversquare Bailli
Avenue Louis 231
10520 Brussel, Belgium
FORMAT
Hybrid Conference
Brussels & Online
REGISTRATION
Join us in Brussels or online for the ICEPS 2026 Conference.
Secure your place and be part of two days of insights, discussions and networking around value creation across the medical device lifecycle.